Biopharma Discovery Problems. Solved.
From large enterprise-wide deployments to single group installations, discover how Genedata Biologics® is used by leading global biopharma, biotechs and CROs to increase efficiency and drive innovation.
Ten years ago, when MorphoSys was looking for a data management solution for their biologics R&D, they quickly realized that the small-molecule-based options available could not handle large-molecule discovery tasks. Then they met Genedata, whose enterprise platform is uniquely built for biotherapeutics. Genedata understood that biologics workflows, as well as protein sequence information, are completely different than the structural information for small molecules, and a lasting partnership was born.
Janssen, Celgene, and Aptevo Make Better Decisions
Genedata Biologics accelerates biotherapeutics R&D processes and provides a structured database with immediate and central access to all information along the discovery workflow. Janssen, Celgene, and Aptevo discuss how they use the platform to mine data, look at trends, and implement machine learning strategies to gain critical business intelligence so they can make better decisions.
Six Reasons Why Crescendo Biologics Uses Genedata
Crescendo Biologics is developing a novel class of small, robust protein therapeutics in the immuno-oncology and next-generation ADC space. Due to the complexity and scale of their product design activities and the vast amounts of data generated during candidate testing, they needed a scalable system to work as a backbone for all their R&D activities. Genedata Biologics supports their entire discovery process, spanning immunization of transgenic mice, lead selection, molecular modification, and final candidate assessments. The platform, referred to as their single source of truth, is crucial for their operations.
Meet the Genedata Community
Genedata Biopharma Partner Symposium
March 23–24, 2022 | Basel, Switzerland
The Genedata Biologics Partner Symposium is a unique interdisciplinary event at the interface between biopharma R&D and IT is your chance to learn how other companies have set up and are using Genedata platforms. Presentations and discussions will focus on innovative applications and new industry requirements, such as novel molecular formats (e.g., multispecifics, TCRs, and AAVs) and increasing automation and standardization in biopharmaceutical R&D. Leading biopharma companies will show how groups have set up, operate, and use Genedata platforms to transform their biotherapeutics research & development and how this results in increased efficiency and throughput.
Pfizer Builds on the Genedata Biopharma E2E Workflow Platform
After conducting a thorough market evaluation to identify an off-the-shelf enterprise system for large-molecule discovery, Pfizer implemented Genedata Biologics as their central repository for their biologics discovery data, including screening, molecular biology, engineering, expression, purification, and analytics.
Immatics Digitalizes CGT Discovery with Genedata Biologics
Leveraging Genedata’s out-of-the-box functionality, Immatics is streamlining CGT processes and increasing R&D efficiency. Genedata's scientific consultants also helped to configure Immatics-specific CGT workflows and integrate laboratory instruments so rollout of the platform was straightforward – and fast.
Selected Customer Presentations
Genedata's customers at leading biopharmaceutical and biotech companies worldwide regularly present how Genedata Biologics is used to advance their R&D activities. Learn how Pfizer, Bayer, UCB, Takeda, AbbVie, GSK, Kymab, Sanofi and others are streamlining processes and increasing the efficiency of their biotherapeutic discovery operations with the Genedata platform.
Our Customers Are Talking
Genedata Enables Data-Informed Decisions
“We are excited to implement the Genedata Biopharma Platform as a central integrated data backbone to streamline the capture, integration, democratization, and analysis of increasingly complex and diverse data types across Genmab’s discovery and clinical workflows."
Mission-Critical Data Centrally Stored in Genedata
“We are rapidly expanding our biotherapeutic R&D activities and needed a scalable, flexible platform that we could quickly and easily implement. We chose Genedata Biologics as it is the only out-of-the-box platform on the market dedicated to large-molecule R&D.”
Scalable Backbone System Supports ADC Discovery
"Genedata Biologics is a key component of our growth plans in the immuno-oncology and next-generation ADC space. Thanks to its flexible architecture, Genedata Biologics can truly support our entire discovery process—right through from the immunization of transgenic mice, to lead selection, molecular modification and final candidate assessments.”
Immunotherapy Discovery Programs Scaled Up
“Genedata Biologics provides a flexible architecture and includes built-in biopharma domain knowledge, which can handle our proprietary bispecific antibody discovery processes. We believe Genedata Biologics will help us to accelerate the discovery of the next generation of immuno-oncology therapeutics.”